Imaging Study for TROP2 Drug in EGFR-Failure Lung Cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new imaging scan (two types of PET/CT) to see how well it tracks tumor response to a TROP2-targeted drug in people with EGFR-mutant lung cancer that stopped responding to standard pills. It aims to improve how doctors measure treatment success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic lung cancer (non-squamous type, not eligible for surgery or radiation to cure it).
- Your cancer cells have a specific change called an EGFR mutation (exon 19 deletion or L858R).
- You have already been treated with a third-generation EGFR pill (like osimertinib) and it stopped working.
- You have at least one tumor measurable on scans (not only skin or bone tumors).
- You are in good general health (able to care for yourself, no serious infections or heart problems, adequate organ function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special PET/CT scan can show how well a Trop2-targeting drug is working in people with advanced lung cancer that has already been treated. It aims to improve how we monitor treatment response.
This trial uses a special PET scan to see if a type of drug called Trop2-ADC is working in people with advanced breast cancer. The scan may help doctors decide if the treatment is right for you.
This study tests whether a new imaging agent called 68Ga-MY6349 can help detect tumors during a PET/CT scan. If you are an adult with a solid tumor (newly diagnosed or already treated), you may be able to take part in this research to see if the new tracer works better than standard imaging.
This trial tests a new treatment called Trop2 CAR-NK, which uses your own immune cells modified to attack lung cancer cells that have a protein called Trop2. It is for people with advanced non-small cell lung cancer that has not responded to standard therapies.
This trial uses a special PET scan to find a protein called Trop-2 on your cancer cells. It helps doctors decide if a targeted treatment (Trop-2 ADC) might work for you.
This research study analyzes lung cancer tissue samples to understand a protein called TROP2 and how it might help guide treatment decisions. You may qualify if you have non-squamous lung cancer and haven't received prior systemic chemotherapy or immunotherapy for advanced disease.
Hear when a new EGFR Activating Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.